×
For best experience we recommend to activate Javascript in your browser.
RELB antibody (AA 248-492)
This anti-RELB antibody is a Rabbit Polyclonal antibody detecting RELB in WB, IHC, IP and ICC. Suitable for Human.
Quick Overview for RELB antibody (AA 248-492) (ABIN7629444)
Target
See all RELB Antibodies
RELB
(V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))
Reactivity
All reactivities for RELB antibodies
Human
Host
All hosts for RELB antibodies
Rabbit
Clonality
All clonalities for RELB antibodies
Polyclonal
Conjugate
All conjugates for RELB antibodies
This RELB antibody is un-conjugated
Application
All applications for RELB antibodies
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
Product Details anti-RELB Antibody
(hide)
Binding Specificity
All epitopes for RELB antibodies
AA 248-492
Purpose
V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB) Polyclonal Antibody
Sequence
Asp248~Asp492
Characteristics
The V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB) Polyclonal Antibody (Species: Human) has been validated for the following applications: WB, IHC, ICC, IP.
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
0.5 mg/mL
Buffer
0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for RELB
(hide)
Target
RELB
(V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))
Alternative Name
RELB
Gene ID
5971
UniProt
Q01201
Pathways
NF-kappaB Signaling , RTK Signaling
Recently viewed
(hide)
Chat with us , powered by LiveChat